All In Biotech

Drug Trial Radar · NCT07326878

Phase I Clinical Trial of Enterovirus Type71 - Coxsackievirus Type A16 Bivalent Vaccine

A Single-center, Randomized, Double-blind, and Placebo Controlled Phase Ⅰ Clinical Trial of the Safety and Preliminary Immunogenicity of Enterovirus Type71 - Coxsackievirus Type A16 Bivalent Vaccine in People Aged 6 Months to 59 Years

Last checked: Nov 20, 2026Latest source record: Jan 8, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingRandomized with 144 participants. This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

144

Planned (sponsor's estimate)

Start

Dec 30, 2025

Primary completion

Aug 15, 2026

Study completion Aug 15, 2027

Sponsor

Sponsor type
Academic, hospital or other
Collaborators
The Second Affiliated Hospital of Chongqing Medical University
First posted
Jan 8, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Sequential
Masking
Double (participant, investigator)
Primary purpose
Prevention
FDA-regulated drug
No
Who can join
All sexes, from 6 months, up to 59 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This is a randomized, double-blinded, placebo-controlled phase I clinical trial to evaluate the safety and preliminary immunogenicity of the Enterovirus Type71 - Coxsackievirus Type A16 bivalent vaccine in subjects ( aged 6 months to 59 years ).

Conditions

  • Hand, Foot and Mouth Disease (HFMD)
  • HFMD
  • Hand, Foot and Mouth Disease

Interventions

  • Low Dose Enterovirus Type71 - Coxsackievirus Type A16 bivalent vaccine, inactivated (human diploid cell)Biological

    Low-dose vaccine,dosage and immunization procedure: 0.1 ml/dose, 2 doses, 28-day interval

  • Medium Dose Enterovirus Type71 - Coxsackievirus Type A16 bivalent vaccine, inactivated (human diploid cell)Biological

    Medium-dose vaccine,dosage and immunization procedure: 0.1 ml/dose, 2 doses, 28-day interval

  • High Dose Enterovirus Type71 - Coxsackievirus Type A16 bivalent vaccine, inactivated (human diploid cell)Biological

    High-dose vaccine,dosage and immunization procedure: 0.1 ml/dose, 2 doses, 28-day interval

  • PlaceboBiological

    Placebo,dosage and immunization procedure: 0.1 ml/dose, 2 doses, 28-day interval

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Safety index - incidence of adverse eventsTime frame: 0- 30 minutes/Day 0 to 7 days/Day 0 to 28 days after each dose

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • The Second Affiliated Hospital of Chongqing Medical University

    Chongqing, Chongqing Municipality, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.